Combating counterfeit drugs
Counterfeit drugs are a serious threat to health care. The World Health Organization WHO assumes that up to ten percent of
the drugs offered worldwide are either counterfeit or of deficient quality.
Identifying counterfeit drugs quickly and cheaply
The mobile compact laboratory GPHF-Minilab® makes it possible to identify counterfeit drugs quickly and cheaply. The Global Pharma Health Fund e.V. (GPHF), which is supported exclusively by Merck and started operations on July 1, 2007, succeeds the “German Pharma Health Fund”, a pharmaceutical industry initiative that promoted numerous health projects in developing countries from 1985 to 2007, including the development and testing of the GPHF-Minilab®.
The mobile compact laboratory GPHF-Minilab® makes it possible to identify counterfeit drugs quickly and cheaply. The Global Pharma Health Fund e.V. (GPHF), which is supported exclusively by Merck and started operations on July 1, 2007, succeeds the “German Pharma Health Fund”, a pharmaceutical industry initiative that promoted numerous health projects in developing countries from 1985 to 2007, including the development and testing of the GPHF-Minilab®.
More than 350 mini-labs in use
Worldwide, more than 350 laboratory units are in use in more than 70 countries. They are mainly being deployed in Africa and Asia, which are especially affected by counterfeit drugs since the preconditions for effective drug control are often lacking in many African and Asian countries.
Worldwide, more than 350 laboratory units are in use in more than 70 countries. They are mainly being deployed in Africa and Asia, which are especially affected by counterfeit drugs since the preconditions for effective drug control are often lacking in many African and Asian countries.
The GPHF-Minilab® is capable of identifying counterfeit or low-quality drugs with simple test methods that are also reliable
in tropical countries.
